Welcome to our dedicated page for Smith & Nephew news (Ticker: SNN), a resource for investors and traders seeking the latest updates and insights on Smith & Nephew stock.
Smith & Nephew plc (NYSE: SNN, LSE: SN) is a global medical technology business whose news flow reflects activity across orthopaedics, sports medicine & ENT, and advanced wound management. Company announcements frequently highlight new product launches, clinical evidence, strategic partnerships and portfolio updates that are relevant to surgeons, healthcare providers and investors following SNN stock.
Recent news has showcased advanced wound management innovations, such as clinical data on the PICO◊ Single Use Negative Pressure Wound Therapy System demonstrating reductions in wound dehiscence, length of stay and costs versus an alternative device in orthopaedic and cardiovascular surgery, and studies on the ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing describing its mechanism in absorbing and dissipating shear forces linked to pressure injury risk.
In Sports Medicine, Smith+Nephew news items have covered the REGENETEN◊ Bioinductive Implant, including randomized controlled trial results and expanded indications to extra-articular ligament injuries, as well as updates on the CARTIHEAL◊ AGILI-C◊ Cartilage Repair Implant, including the establishment of a Category I CPT code recognising its clinical significance and adoption. Announcements also describe launches such as the Q-FIX™ KNOTLESS All-Suture Anchor and the CENTRIO Platelet-Rich-Plasma System for chronic exuding wounds.
Orthopaedics-related releases include the launch of the TRIGEN™ MAX Tibia Nailing System for tibial fractures and the expansion of CORIOGRAPH™ Pre-Op Planning and Modeling Services to total shoulder arthroplasty, alongside references to the AETOS◊ Shoulder System. Strategic and investor-focused news covers topics such as the RISE strategy, medium-term financial targets, and acquisitions like Integrity Orthopaedics and its Tendon Seam™ rotator cuff repair technology.
Visitors to this SNN news page can review these updates in one place, tracking how Smith & Nephew presents clinical data, regulatory milestones, portfolio expansions, partnerships with organisations such as UFC and Wimbledon, and capital markets communications that shape the company’s profile in the global medical technology sector.
Smith+Nephew (NYSE: SNN) has released a systematic literature review and meta-analysis highlighting its VISIONAIRE Patient-Specific Instrumentation (PSI), which has shown enhanced alignment accuracy and efficiency in Total Knee Arthroplasty (TKA). The analysis included 25 studies, indicating significant improvements such as a 40% reduction in outlier odds for mechanical axis alignment, decreased operating room time, and an 11.1% reduction in hospital stay length. The findings, published in the Archives of Orthopaedic and Trauma Surgery, demonstrate that VISIONAIRE PSI leads to better patient outcomes and lower total hospital costs compared to conventional TKA methods.
Smith+Nephew (NYSE:SNN) announced that its LEAF Patient Monitoring System received an Innovative Technology designation from Vizient, the largest healthcare performance improvement company in the U.S. The award highlights products that enhance clinical care and safety. The LEAF System, the first wearable solution meeting NPIAP guidelines, has shown to improve adherence to patient turning protocols by 98% and reduce hospital-acquired pressure injuries by 73%. Its implementation resulted in estimated annual cost savings of up to $1.8 million in a critical care unit. Pressure injuries represent a rising hospital-acquired complication, costing roughly $11 billion in preventable treatments annually.
On November 1, 2022, Smith+Nephew (NYSE:SNN) introduced the JOURNEY II ROX Total Knee Solution, designed for total knee arthroplasty. This innovative solution combines advanced bearing materials with cementless tibia fixation, enhancing surgical efficiency. It integrates technologies like CONCELOC Advanced Porous Titanium and OXINIUM Oxidized Zirconium for maximum performance. Compatible with the CORI Surgical System, it supports robotics-assisted procedures. Smith+Nephew will showcase this product at the AAHKS Annual Meeting, highlighting its commitment to advancing knee surgery technology.
Smith+Nephew (LSE:SN, NYSE:SNN) announces the successful first cases of revision knee replacement using its CORI Surgical System on August 17, 2022. The company is the first in orthopaedics to obtain FDA 510(k) clearance for a robotic-assisted platform for revision indications. This innovation allows surgeons to create patient-specific 3D models and improve precision in surgery. The CORI system now supports total, partial, and revision knee arthroplasties, enhancing surgical efficiency and patient care.
Smith+Nephew (NYSE:SNN) announced on Sept. 21, 2022, an expansion of its medical education curriculum via advanced simulation technologies, including virtual reality and augmented reality. Healthcare professionals can now access training in orthopaedics, robotics, and sports medicine globally. A survey revealed that 90% of participants support the use of virtual reality in future training. Smith+Nephew aims to enhance surgical education and patient outcomes by integrating cutting-edge technology into its Academy program, with new educational modules launching soon.
Smith+Nephew (NYSE: SNN) announced significant findings from a randomized controlled trial for its REGENETEN Bioinductive Implant in rotator cuff repair. The interim results showed an 86% reduction in re-tear rates, with a rate of 3.5% in patients receiving the implant compared to 25% for traditional repair alone. The study was presented at the SECEC-ESSE Congress in Dublin. These results may enhance recovery for approximately 545,000 annual procedures globally, highlighting the implant's potential impact on patient outcomes and market positioning.
Smith+Nephew (NYSE: SNN) announces the OXINIUM Technology Tour of Change will be featured at the Pro Football Hall of Fame from August 4-6, 2022, to educate retired players and the community on joint replacement technology. The company partners with Hall of Fame Health to provide access to OXINIUM products. OXINIUM Technology has been recognized for its superior performance in hip and knee replacements over 20 years, showing low revision rates. Testimonials from Hall of Famers emphasize the technology's positive impact on their lives.
Smith+Nephew (LSE: SN, NYSE: SNN) is showcasing advanced joint repair solutions at the AOSSM Annual Meeting in Colorado from July 13-17, 2022. Key highlights include the REGENETEN Bioinductive Implant, aimed at treating 17 million individuals with rotator cuff diseases in the U.S., which has shown potential to expedite healing and reduce re-tears. Other innovations include the Reimagine Reconstruction portfolio for knee injuries and the CAP-FIX Suture Passer for hip repairs. The event will also feature live surgery demos and educational opportunities for surgeons.
Smith+Nephew (NYSE:SNN) has launched the WOUND COMPASS™ Clinical Support App, aimed at assisting healthcare professionals in wound assessment and decision-making. The app addresses practice variation, which negatively affects patient outcomes in chronic wound care. Validated by over 70 clinicians, it enhances nurse confidence in assessments, with 83% of non-specialists reporting it simplifies evaluations. Available on both Apple and Android, the app categorizes wounds and offers tailored treatment guidance. This innovation is part of Smith+Nephew’s commitment to improving patient care and outcomes.
Smith+Nephew (NYSE: SNN) successfully performed its first robotic-assisted surgery using the LEGION CONCELOC Cementless Total Knee System. Conducted by Dr. Cyna Khalily in Louisville, KY, this milestone enhances its portfolio of cementless knee implants and robotic technology. The procedure employs the CORI Surgical System, designed to optimize surgical efficiency by eliminating preoperative CT imaging, thus reducing costs and radiation exposure. This innovation reflects Smith+Nephew's commitment to improving surgical outcomes and employing advanced materials for knee arthroplasty.